Endonovo Therapeutics has received approval from the Taiwan Food and Drug Administration (TFDA) for its Pulsed Electro Magnetic Field (PEMF) technology, SofPulse.

EverMed Medical Enterprises, the distribution partner of Endonovo, will supply this device in the country.

By starting the product registration process with Taiwan's National Healthcare Insurance (NHI), the commercialisation of the device begins in the country.

EverMed will manage the registration of the medical device under the NHI programme and create billing codes for its utilisation in healthcare facilities across the nation.

Initially, the company will focus on selling the device in multiple Taiwanese hospital surgical markets.

It will target four surgical specialities, including plastic surgery, spinal surgery, orthopaedic surgery and cardiovascular surgery.

EverMed CEO George Wang said: “TFDA approval of SofPulse is a significant advancement for healthcare in Taiwan and strengthens our product portfolio.

“Our rigorous evaluations and clinical assessments have consistently highlighted the unique benefits and advantages of SofPulsePEMF medical devices in assisting surgical recovery, inflammation reduction and post-operative non-opioid pain management.”

Endonovo is presently organised into two divisions, including Legacy and Build Up Strategy.

Legacy is a commercial-stage developer focused on offering non-invasive wearable Electroceuticals therapeutic devices for general wellness, pain relief and wound curatives, with various products marketed under the SofPulse brand name.

The Build Up Strategy is focused on acquiring complementary speciality service providers in the medical technology as well as construction industries.